– WuXi Diagnostics secured a US$150m Series B financing round to accelerate market penetration in the global diagnostics sector.
– The round was joined by new investors including Thermo Fisher, Shiyu Capital, ABC International, Sunland Capital, and CCBI Tech Venture.
– WuXi Diagnostics will deploy funds to strengthen its open-access innovation enabling platform, advance its integrated diagnostics R&D pipeline, and accelerate market penetration in the global diagnostics sector.
– WuXi Diagnostics is the first platform company in China focusing on integrated diagnostics. Since its establishment in 2018, WuXi Diagnostics has continuously promoted the clinical practice of integrated diagnostics by virtue of its open-access innovation enabling platform, centered on multi-omics clinical data from multidisciplinary technologies.

– OmniLife has launched an open $250,000 CF round of investment through Wunderfund.co to enable the passionate organ donation community to participate in providing innovative solutions to the industry.
– Open to non-institutional, private investors with lower investment minimums and no accreditation requirements, the funds raised with this crowd-sourced opportunity will be used to support the commercialization of the company’s newest product, a communication-centric workflow tool allowing providers to collaborate on cases together to increase efficiency, transparency and coordination in order to place more organs and tissues and save more lives.
– Over the last four years, OmniLife has developed the largest collaboration and communication network specifically for transplant and donation professionals, with new organizations and partners joining every day.

– Carevive Systems (Carevive), the leading oncology-focused health technology company centered on understanding and improving the cancer patient experience, has today announced the completion of a Series C equity investment of $18 million.
– The oversubscribed $18 million equity round was led by Philips Health Technology Ventures, and also includes Debiopharm Innovation Fund, and OurCrowd’s digital health fund, Qure Ventures, as well as prior investors HLM Venture Partners, LRVHealth, Cerner, and founder Madelyn Trupkin Herzfeld.

– Tele-Behavioral Health Service Valera Health Closes $3.8 Million
– The company raised $3.8m in Series A funding.
– The round was led by AXA Venture Partners (AVP) with participation from Windham Ventures, Figure Eight Investments, and notable mental health expert Tom Insel, MD (former Director of the National Institute of Mental Health).

– Equip, a health tech company pioneering a program that virtually delivers evidence-based eating disorder treatment to families at home, today announced it has closed $13m in Series A financing, bringing its total funds raised to date to $17m.
– The Series A round was led by Optum Ventures, with participation from new investor .406 Ventures and existing investor F-Prime Capital, who led the company’s prior Seed round.
– Equip’s mission is to make gold-standard eating disorder treatment accessible to all people through Family-Based Treatment (FBT) – the standard of care which empowers families to help their loved ones through recovery.

– MedLumics, a privately held medical device company developing AblaView®, the first optically-guided real-time ablation catheter system for the treatment of Atrial Fibrillation (AF), announced today that it has closed an upsized EUR 18 million (USD 21.7 million) financing round.
– MedLumics’ optical catheter displays lesion creation in real-time providing the physician with direct visual confirmation of conduction tissue denaturation.
– This round was led by Asabys Partners, along with new investors, VI Partners Swiss Innovation and CDTI Innvierte Economía, and existing investors Andera Partners, Caixa Capital Risc and Innogest Capital II.
– MedLumics is now ready to initiate first in-human regulatory clinical studies and automate scalable product manufacturing.